Clinical characteristics, genetic basis and healthcare resource utilisation and costs in patients with catecholaminergic polymorphic ventricular tachycardia: A retrospective cohort study
Cheuk To Chung, Sharen Lee, Jiandong Zhou, Oscar Hou In Chou, Teddy Tai Loy Lee, Keith Sai Kit Leung, Kamalan Jeevaratnam, Wing Tak Wong, Tong Liu and Gary Tse 2022. Clinical characteristics, genetic basis and healthcare resource utilisation and costs in patients with catecholaminergic polymorphic ventricular tachycardia: A retrospective cohort study. Reviews in Cardiovascular Medicine. 23 (8).
|Authors||Cheuk To Chung, Sharen Lee, Jiandong Zhou, Oscar Hou In Chou, Teddy Tai Loy Lee, Keith Sai Kit Leung, Kamalan Jeevaratnam, Wing Tak Wong, Tong Liu and Gary Tse|
Background: This study examined the clinical characteristics, genetic basis, healthcare utilisation and costs of catecholaminergic ventricular tachycardia (CPVT) patients from a Chinese city. Methods: This was a territory-wide retrospective cohort study of consecutive CPVT patients at public hospitals or clinics in Hong Kong. Healthcare resource utilisation for accident and emergency (A&E), inpatient and outpatient attendances were analysed over 19 years (2001–2019) followed by calculations of annualised costs (in USD). Results: Sixteen patients with a median presentation age (interquartile range (IQR) of 11 (9–14) years old) were included. Fifteen patients (93.8%) were initially symptomatic. Ten patients had both premature ventricular complexes (PVCs) and ventricular tachycardia/fibrillation (VT/VF). One patient had PVCs without VT/VF. Genetic tests were performed on 14 patients (87.5%). Eight (57.1%) tested positive for the ryanodine receptor 2 (RyR2) gene. Seven variants have been described elsewhere (c.14848G>A, c.12475C>A, c.7420A>G, c.11836G>A, c.14159T>C, c.10046C>T and c.7202G>A).c.14861C>G is a novel RyR2 variant not been reported outside this cohort. Patients were treated with beta-blockers (n = 16), amiodarone (n = 3) and verapamil (n = 2). Sympathectomy (n = 8) and implantable-cardioverter defibrillator implantation (n = 3) were performed. Over a median follow-up of 13.3 years (IQR: 8.4–18.1) years, six patients exhibited incident VT/VF. At the patient level, the median (IQR) annualised costs for A&E, inpatient and outpatient attendances were $66 (40–95), $10521 (5240–66887) and $791 (546–1105), respectively. Conclusions: All patients presented before the age of 19. The yield of genetic testing was 57%. The most expensive attendance type was inpatient stays, followed by outpatients and A&E attendances.
|Keywords||CPVT; HCRU; Tachycardia; Genetics|
|Journal||Reviews in Cardiovascular Medicine|
|Journal citation||23 (8)|
|Online||05 Aug 2022|
|Publication process dates|
|Accepted||20 Jun 2022|
|Deposited||24 May 2023|
3views this month
0downloads this month